4MB.F ALPHAHELIX MOL.DIAGN. SK1
- Market cap
- EUR 684K
- P/E
- 1.0x
- P/B
- 1.13x
- ROE
- 119.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 4MB.F undervalued?
Graham numberThe Graham number of ALPHAHELIX MOL.DIAGN. SK1 cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ALPHAHELIX MOL.DIAGN. SK1 fundamental analysis
No fundamental analysis for ALPHAHELIX MOL.DIAGN. SK1 yet.
ALPHAHELIX MOL.DIAGN. SK1 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ALPHAHELIX MOL.DIAGN. SK1
Level Bio AB (publ) manufactures and distributes cutting-edge solutions in the Nordic region and internationally. It develops and manufactures diagnostic kits for the clinical market, as well as act as a distributor and full service partner to molecular biology labs in the Nordics. The company was formerly known as AlphaHelix Molecular Diagnostics AB (publ) and changed its name to Level Bio AB (publ) in May 2024. Level Bio AB (publ) was incorporated in 1998 and is headquarte…
Full company profileALPHAHELIX MOL.DIAGN. SK1 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ALPHAHELIX MOL.DIAGN. SK1 annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 34.3M | 26.1M | 25.1M | 32.4M | 35.8M |
| Gross Profit | 15.3M | 12.3M | 13.5M | 17.1M | 16.6M |
| Operating Income | -1.53M | -8.93M | -7.28M | -2.68M | -868K |
| EBITDA | -153K | -7.49M | -5.88M | -1.29M | -117K |
| Net Income | -2.22M | -9.48M | -7.87M | -3.54M | 7.55M |
| EPS | -0.04 | -0.15 | -0.12 | -0.05 | 0.11 |
| Balance Sheet | |||||
| Total Assets | 28.8M | 19.1M | 15.4M | 14.1M | 19.6M |
| Total Liabilities | 8.91M | 8.68M | 11.2M | 13.4M | 13.3M |
| Shareholders' Equity | 19.9M | 10.4M | 4.18M | 637K | 6.30M |
| Cash & Short-term Investments | 7.84M | 3.63M | 1.08M | 2.48M | 67.0K |
| Cash Flow | |||||
| Operating Cash Flow | 2.87M | -5.45M | -4.46M | 820K | -1.94M |
| Capital Expenditure | 288K | 42.5K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | 2.58M | -5.49M | -4.46M | 820K | -1.94M |
| Ratios | |||||
| ROE | -11.2% | -91.0% | -188.5% | -555.5% | 119.9% |
| ROA | -7.7% | -49.6% | -51.2% | -25.2% | 38.5% |
| Net Profit Margin | -6.5% | -36.3% | -31.4% | -10.9% | 21.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ALPHAHELIX MOL.DIAGN. SK1 dividends
ALPHAHELIX MOL.DIAGN. SK1 has not paid dividends in the last 4 fiscal years.
Who owns ALPHAHELIX MOL.DIAGN. SK1
- Insiders 0.00%
- Institutions 0.01%
- Public & others 99.99%
- Shares outstanding 68.4M
- Free float 28.1M
ALPHAHELIX MOL.DIAGN. SK1 company profile
- Company name
- ALPHAHELIX MOL.DIAGN. SK1
- Ticker
- 4MB.F
- ISIN
- SE0000885501
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
- Fiscal year end
- December
- Address
- Västra finnbodavägen 4B, Stockholm, Sweden, 131 30
- Phone
- 46 86 26 76 00
- Website
- levelbio.se
About ALPHAHELIX MOL.DIAGN. SK1
Level Bio AB (publ) manufactures and distributes cutting-edge solutions in the Nordic region and internationally. It develops and manufactures diagnostic kits for the clinical market, as well as act as a distributor and full service partner to molecular biology labs in the Nordics. The company was formerly known as AlphaHelix Molecular Diagnostics AB (publ) and changed its name to Level Bio AB (publ) in May 2024. Level Bio AB (publ) was incorporated in 1998 and is headquartered in Stockholm, Sweden.
ALPHAHELIX MOL.DIAGN. SK1 management
2- Mr. Joakim GranemoCEO & Director · born 1986
- Ms. Ulrica KarlssonCFO & Director · born 1969